Total Payments
$361.71
2024 Payments
$176.53
Companies
13
Transactions
17
Medicare Patients
17,106
Medicare Billing
$5.7M
Payment Breakdown by Category
Food & Beverage$326.00 (90.1%)
Education$35.71 (9.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $326.00 | 14 | 90.1% |
| Education | $35.71 | 3 | 9.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Tactile Systems Technology Inc | $72.90 | 2 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $69.28 | 3 | $0 (2024) |
| Astellas Pharma US Inc | $44.50 | 2 | $0 (2024) |
| Mirati Therapeutics, Inc. | $26.60 | 1 | $0 (2024) |
| BTG International, Inc. | $24.27 | 1 | $0 (2017) |
| Daiichi Sankyo Inc. | $19.29 | 1 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $19.10 | 1 | $0 (2023) |
| BeiGene USA, Inc. | $18.00 | 1 | $0 (2020) |
| Merck Sharp & Dohme LLC | $16.86 | 1 | $0 (2024) |
| PUMA BIOTECHNOLOGY, INC. | $15.20 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $176.53 | 8 | Novartis Pharmaceuticals Corporation ($69.28) |
| 2023 | $19.10 | 1 | E.R. Squibb & Sons, L.L.C. ($19.10) |
| 2022 | $72.90 | 2 | Tactile Systems Technology Inc ($72.90) |
| 2021 | $27.12 | 2 | PUMA BIOTECHNOLOGY, INC. ($15.20) |
| 2020 | $18.00 | 1 | BeiGene USA, Inc. ($18.00) |
| 2019 | $11.50 | 1 | PFIZER INC. ($11.50) |
| 2018 | $12.29 | 1 | Seattle Genetics, Inc. ($12.29) |
| 2017 | $24.27 | 1 | BTG International, Inc. ($24.27) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2024 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $21.93 | General |
| 09/17/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $26.60 | General |
| Category: Oncology | ||||||
| 08/29/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: Oncology | ||||||
| 07/29/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: ONCOLOGY | ||||||
| 04/29/2024 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $22.57 | General |
| 04/15/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: Oncology | ||||||
| 03/21/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug), PLUVICTO | Food and Beverage | In-kind items and services | $33.25 | General |
| Category: Oncology | ||||||
| 03/23/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.10 | General |
| Category: Oncology | ||||||
| 12/08/2022 | Tactile Systems Technology Inc | Flexitouch Plus (Device), entre | Food and Beverage | In-kind items and services | $56.17 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 11/10/2022 | Tactile Systems Technology Inc | Flexitouch Plus (Device), entre | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/21/2021 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $15.20 | General |
| Category: ONCOLOGY | ||||||
| 06/10/2020 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Oncology | ||||||
| 09/06/2019 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $11.50 | General |
| Category: ONCOLOGY | ||||||
| 04/11/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 08/28/2017 | BTG International, Inc. | VISTOGARD-20 (Drug) | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: TOXICITY ANTIDOTE 5 FU TOXICITY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 61 | 3,853 | 68,418 | $4.5M | $821,191 |
| 2022 | 65 | 4,274 | 96,156 | $6.4M | $1.3M |
| 2021 | 70 | 4,506 | 118,539 | $7.3M | $1.9M |
| 2020 | 77 | 4,473 | 127,500 | $6.9M | $1.7M |
Total Patients
17,106
Total Services
410,613
Medicare Billing
$5.7M
Procedure Codes
273
All Medicare Procedures & Services
273 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 17 | 10,300 | $1.5M | $445,060 | 29.5% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 11 | 1,734 | $429,928 | $58,307 | 13.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 240 | 449 | $120,925 | $40,648 | 33.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 113 | 334 | $278,713 | $33,800 | 12.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 109 | 189 | $68,662 | $25,017 | 36.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 252 | 350 | $63,473 | $21,648 | 34.1% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 23 | 19,500 | $97,500 | $16,984 | 17.4% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 17 | 6,990 | $146,790 | $16,249 | 11.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 349 | 1,375 | $85,250 | $14,213 | 16.7% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 39 | 189 | $13,230 | $13,230 | 100.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 372 | 1,611 | $56,385 | $12,239 | 21.7% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 24 | 7,930 | $71,370 | $10,919 | 15.3% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 18 | 91 | $358,358 | $10,480 | 2.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 70 | 97 | $29,528 | $8,966 | 30.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 89 | 164 | $49,856 | $7,641 | 15.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 328 | 890 | $16,910 | $7,453 | 44.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 94 | 480 | $50,400 | $5,678 | 11.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 33 | 33 | $19,901 | $5,442 | 27.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 19 | 105 | $26,162 | $5,411 | 20.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 61 | 198 | $30,096 | $4,367 | 14.5% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 35 | 420 | $22,680 | $3,828 | 16.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $15,866 | $3,810 | 24.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 24 | 71 | $28,906 | $3,577 | 12.4% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 55 | 185 | $16,835 | $3,300 | 19.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 21 | 21 | $12,451 | $2,829 | 22.7% |
About Dr. Matthew Skelton, MD
Dr. Matthew Skelton, MD is a Hematology & Oncology healthcare provider based in Roanoke, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689614919.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Skelton, MD has received a total of $361.71 in payments from pharmaceutical and medical device companies, with $176.53 received in 2024. These payments were reported across 17 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($326.00).
As a Medicare-enrolled provider, Skelton has provided services to 17,106 Medicare beneficiaries, totaling 410,613 services with total Medicare billing of $5.7M. Data is available for 4 years (2020–2023), covering 273 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Roanoke, VA
- Active Since 06/07/2006
- Last Updated 02/05/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1689614919
Products in Payments
- Flexitouch Plus (Device) $72.90
- PLUVICTO (Drug) $36.03
- LUTATHERA (Drug) $33.25
- KRAZATI (Drug) $26.60
- VISTOGARD-20 (Drug) $24.27
- Enhertu (Drug) $19.29
- OPDIVO (Biological) $19.10
- BRUKINSA (Drug) $18.00
- KEYTRUDA (Biological) $16.86
- NERLYNX (Drug) $15.20
- ADCETRIS (Biological) $12.29
- XTANDI (Drug) $11.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Roanoke
Amanda Gillespie-Twardy, M.d, M.D
Hematology & Oncology — Payments: $15,362
Hematology & Oncology $15,362
Mark Kochenderfer, Md, MD
Hematology & Oncology — Payments: $12,819
Hematology & Oncology $12,819
Dr. Padmaja Mallidi, M.d, M.D
Hematology & Oncology — Payments: $1,580
Hematology & Oncology $1,580
Dr. Harry Mccoy, M.d, M.D
Hematology & Oncology — Payments: $544.52
Hematology & Oncology $544.52
Mrs. Kirsten Hinson, Fnp-C, FNP-C
Hematology & Oncology — Payments: $421.40
Hematology & Oncology $421.40
Joshua Morales, Md, MD
Hematology & Oncology — Payments: $412.41
Hematology & Oncology $412.41